Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27691432)
Watch
English
Better therapeutic trials in ovarian cancer
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
review article
1 reference
stated in
Europe PubMed Central
title
Better therapeutic trials in ovarian cancer
(English)
1 reference
stated in
PubMed
main subject
ovarian cancer
1 reference
based on heuristic
inferred from title
author
Amit M Oza
1 reference
stated in
ORCID Public Data File 2021
author name string
Bookman MA
series ordinal
1
1 reference
stated in
PubMed
Gilks CB
series ordinal
2
1 reference
stated in
PubMed
Kohn EC
series ordinal
3
1 reference
stated in
PubMed
Kaplan KO
series ordinal
4
1 reference
stated in
PubMed
Huntsman D
series ordinal
5
1 reference
stated in
PubMed
Aghajanian C
series ordinal
6
1 reference
stated in
PubMed
Birrer MJ
series ordinal
7
1 reference
stated in
PubMed
Ledermann JA
series ordinal
8
1 reference
stated in
PubMed
Oza AM
series ordinal
9
1 reference
stated in
PubMed
Swenerton KD
series ordinal
10
1 reference
stated in
PubMed
language of work or name
English
0 references
publication date
April 2014
1 reference
stated in
PubMed
published in
Journal of the National Cancer Institute
1 reference
stated in
PubMed
volume
106
1 reference
stated in
PubMed
issue
4
1 reference
stated in
PubMed
page(s)
dju029
1 reference
stated in
PubMed
cites work
ARID1A mutations in endometriosis-associated ovarian carcinomas
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
20 March 2017
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
20 March 2017
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
20 March 2017
Integrated genomic analyses of ovarian carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
20 March 2017
I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
20 March 2017
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
20 March 2017
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
7 April 2017
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
New insights into the pathogenesis of ovarian carcinoma: time to rethink ovarian cancer screening
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
A comparison of phase II study strategies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
Precursors to pelvic serous carcinoma and their clinical implications
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
Speeding up the evaluation of new agents in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982885
retrieved
29 September 2017
Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1093%2FJNCI%2FDJU029
retrieved
21 January 2018
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1093%2FJNCI%2FDJU029
retrieved
21 January 2018
Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1093%2FJNCI%2FDJU029
retrieved
21 January 2018
Fatal necrosis of the hand.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1093%2FJNCI%2FDJU029
retrieved
21 January 2018
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24627272
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Ovarian and extraovarian endometriosis-associated cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24627272
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24627272
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Grading ovarian serous carcinoma using a two-tier system
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24627272
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1093/JNCI/DJU029
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
4302993
OpenCitations bibliographic resource ID
4302993
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
4302993
PMC publication ID
3982885
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
4302993
PubMed publication ID
24627272
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
4302993
ResearchGate publication ID
260810273
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
